Developer docs
API playgroundTry for free, no card

Search company profiles

CoLabs

Full company profile

uuid0002baq

Namestring
CoLabs
Legal namestring
CoLabs International Corp
Websiteurl
colabsintl.com
Company typeenum
Private
Founded yearint
2008
Descriptiontext

CoLabs International Corp is a Nevada-incorporated biotechnology company headquartered in Huntington Beach, California, that states its purpose is to offer products reducing the unwanted absorption of drugs into the skin — effectively a topical dermal-barrier technology intended to limit systemic drug uptake. Founded in 2008, the firm remains in a pre-launch commercial phase: its website (colabsintl.com) carries only "Launching Soon" placeholder text, no product catalog, no pricing, and no technology specifications are disclosed in the available sources, and core technology is explicitly listed as "not disclosed" with no patents or trademarks on file.

The company has raised approximately $7.49M across six documented funding events spanning 2013 through 2023, including a $1.5M round in June 2013, a $270K round in January 2018, two larger rounds in early 2021 totaling roughly $5.4M ($2.4M on 2021-01-28 and $3.005M on 2021-02-08), a $315K initial sale from a $600K SEC Form D exempt offering filed 2023-05-23, and an earlier $315K round on 2023-02-24. Investors and lead investors are undisclosed across all rounds. Leadership consists of Founder and CEO Laura Cohen and Co-founder and COO Lisa LeBlanc; the company operates with 1-10 employees.

The planned go-to-market appears to be direct-to-consumer e-commerce through the company's own storefront, evidenced by 'Shop' and 'Cart' pages and a newsletter signup offering 10% off a first purchase. There are no named customers, B2B contracts, distribution partnerships, or revenue figures in the source material, and the company carries no certifications, regulatory clearances (FDA/CE/etc.), or disclosed clinical data. A separate entity referenced as Co.Labs in Saskatchewan received CAD funding from PrairiesCan in April 2026; the source flags this as likely unaffiliated with CoLabs International Corp.

Short descriptiontext

CoLabs International Corp is a pre-launch biotechnology company developing products that reduce unwanted drug absorption through the skin. The Nevada-incorporated firm plans a direct-to-consumer e-commerce launch via its own storefront at colabsintl.com.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersHuntington Beach, United States
HQ citystring
Huntington Beach
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
topical drug delivery, skin absorption barrier, biopharmaceutical products, dermal drug prevention, consumer biotech products
Industry1 code
PRIMARYCRADAHAL
Functional Beverages (Vitamins, Probiotics, Nootropics, etc.)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Non-Alcoholic Beverages (Coffee, Tea, Soft Drinks, Water)
Product category
Topical Drug Delivery / Consumer Biotechnology
Social media profiles2 records
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

CoLabs develops consumer-facing biotechnology products intended to reduce the unwanted absorption of drugs into the skin. The company plans to distribute these topical barrier products directly to end consumers via its own e-commerce website (colabsintl.com). No specific named SKUs, pricing, or technical specifications are publicly disclosed, and the storefront remains in a "Launching Soon" pre-launch state.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

CoLabs International Corp operates a website (colabsintl.com) that currently displays only a placeholder 'Launching Soon' page with generic sections for 'Featured Products' and a 'Shop' page. No specific products, services, or named offerings are described in the available sources. The website contains only template placeholder text (e.g., 'Generate excitement', 'Grab interest', 'Feature something') with no actual product catalog, pricing, or service descriptions.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMinorTypeOthers
Description

CoLabs International Corp filed a Form D notice with the SEC for an exempt securities offering of $600,000, involving multiple executives and promoters based in Huntington Beach, California. The initial sale targets $315,000 with a minimum investment of $15,000 per investor.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers6 records
TypeDirect peer
Description

Noven Pharmaceuticals (a Hisamitsu subsidiary) develops transdermal drug-delivery systems. It is directly comparable to CoLabs because both operate at the intersection of skin and drug absorption, though Noven enables absorption while CoLabs aims to reduce it.

TypeDirect peer
Description

Crescita Therapeutics is a Canadian specialty pharmaceutical company focused on topical drug delivery and skin science. Comparable in scale and topical-pharmaceutical focus, making it a relevant small-cap comparable for CoLabs' planned product category.

TypeBroad incumbent
Description

Dermavant Sciences develops and commercializes therapeutics in dermatology. Comparable as a dermatology-focused player working on skin-applied pharmaceutical products, though Dermavant is more developed and focused on delivering therapeutics rather than blocking absorption.

TypeDirect peer
Description

AdhexPharma specializes in transdermal drug-delivery patches and topical pharmaceutical systems. Comparable given the shared focus on transdermal/skin drug delivery and pharmaceutical formulation, even though Adhex enables rather than blocks absorption.

5Tapemark
TypeDirect peer
Description

Tapemark is a contract manufacturer specializing in topical and transdermal drug-delivery products. Comparable because its business is built around skin-based pharmaceutical applications and topical formulations — the same product surface area CoLabs is targeting.

TypeEmerging player
Description

Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on dermatological and immunological conditions. Comparable as a small-cap dermatology biotech with a similar development-stage profile to CoLabs.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

CoLabs

Topical Drug Delivery / Consumer Biotechnologycolabsintl.com

CoLabs International Corp is a pre-launch biotechnology company developing products that reduce unwanted drug absorption through the skin. The Nevada-incorporated firm plans a direct-to-consumer e-commerce launch via its own storefront at colabsintl.com.

What CoLabs does

CoLabs International Corp is a Nevada-incorporated biotechnology company headquartered in Huntington Beach, California, that states its purpose is to offer products reducing the unwanted absorption of drugs into the skin — effectively a topical dermal-barrier technology intended to limit systemic drug uptake. Founded in 2008, the firm remains in a pre-launch commercial phase: its website (colabsintl.com) carries only "Launching Soon" placeholder text, no product catalog, no pricing, and no technology specifications are disclosed in the available sources, and core technology is explicitly listed as "not disclosed" with no patents or trademarks on file.

The company has raised approximately $7.49M across six documented funding events spanning 2013 through 2023, including a $1.5M round in June 2013, a $270K round in January 2018, two larger rounds in early 2021 totaling roughly $5.4M ($2.4M on 2021-01-28 and $3.005M on 2021-02-08), a $315K initial sale from a $600K SEC Form D exempt offering filed 2023-05-23, and an earlier $315K round on 2023-02-24. Investors and lead investors are undisclosed across all rounds. Leadership consists of Founder and CEO Laura Cohen and Co-founder and COO Lisa LeBlanc; the company operates with 1-10 employees.

The planned go-to-market appears to be direct-to-consumer e-commerce through the company's own storefront, evidenced by 'Shop' and 'Cart' pages and a newsletter signup offering 10% off a first purchase. There are no named customers, B2B contracts, distribution partnerships, or revenue figures in the source material, and the company carries no certifications, regulatory clearances (FDA/CE/etc.), or disclosed clinical data. A separate entity referenced as Co.Labs in Saskatchewan received CAD funding from PrairiesCan in April 2026; the source flags this as likely unaffiliated with CoLabs International Corp.

CoLabs firmographics

Firmographics
Name
CoLabs
Legal name
CoLabs International Corp
Website
https://colabsintl.com
Company type
Private
Founded year
2008
Operating status
Operating
Headcount range
1–10 employees
Short description
CoLabs International Corp is a pre-launch biotechnology company developing products that reduce unwanted drug absorption through the skin. The Nevada-incorporated firm plans a direct-to-consumer e-commerce launch via its own storefront at colabsintl.com.
Ownership category
akta.pro rank

CoLabs industry classification

Industry
Product category
Topical Drug Delivery / Consumer Biotechnology
akta.pro industry
PRIMARYCRADAHAL
Functional Beverages (Vitamins, Probiotics, Nootropics, etc.)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Non-Alcoholic Beverages (Coffee, Tea, Soft Drinks, Water)

Keywords

  • Topical drug delivery
  • Skin absorption barrier
  • Biopharmaceutical products
  • Dermal drug prevention
  • Consumer biotech products

Where CoLabs is headquartered

Location

Headquarters

HQ city
Huntington Beach
HQ country
United States
HQ region
North America

Offices1 record

Markets served

CoLabs business model

Business model
GTM type
B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Personnel, Marketing or Sales, Operations

Distribution channels1 record

Marketing channels1 record

CoLabs product offering

Product offering

Core offering

CoLabs develops consumer-facing biotechnology products intended to reduce the unwanted absorption of drugs into the skin. The company plans to distribute these topical barrier products directly to end consumers via its own e-commerce website (colabsintl.com). No specific named SKUs, pricing, or technical specifications are publicly disclosed, and the storefront remains in a "Launching Soon" pre-launch state.

Product overview

CoLabs International Corp operates a website (colabsintl.com) that currently displays only a placeholder 'Launching Soon' page with generic sections for 'Featured Products' and a 'Shop' page. No specific products, services, or named offerings are described in the available sources. The website contains only template placeholder text (e.g., 'Generate excitement', 'Grab interest', 'Feature something') with no actual product catalog, pricing, or service descriptions.

Differentiator

Problem solved

Functional benefit

Companies that use CoLabs

Customer profile

Ideal customer profiles1 record

CoLabs technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

CoLabs partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • SEC (Securities and Exchange Commission)minorOthersCoLabs International Corp filed a Form D notice with the SEC for an exempt securities offering of $600,000, involving multiple executives and promoters based in Huntington Beach, California. The initial sale targets $315,000 with a minimum investment of $15,000 per investor.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

CoLabs competitors and assessment

Company assessment

Direct peers

  • Noven Pharmaceuticals: Noven Pharmaceuticals (a Hisamitsu subsidiary) develops transdermal drug-delivery systems. It is directly comparable to CoLabs because both operate at the intersection of skin and drug absorption, though Noven enables absorption while CoLabs aims to reduce it.
  • Crescita Therapeutics: Crescita Therapeutics is a Canadian specialty pharmaceutical company focused on topical drug delivery and skin science. Comparable in scale and topical-pharmaceutical focus, making it a relevant small-cap comparable for CoLabs' planned product category.
  • AdhexPharma: AdhexPharma specializes in transdermal drug-delivery patches and topical pharmaceutical systems. Comparable given the shared focus on transdermal/skin drug delivery and pharmaceutical formulation, even though Adhex enables rather than blocks absorption.
  • Tapemark: Tapemark is a contract manufacturer specializing in topical and transdermal drug-delivery products. Comparable because its business is built around skin-based pharmaceutical applications and topical formulations — the same product surface area CoLabs is targeting.

Broad incumbents

  • Dermavant Sciences: Dermavant Sciences develops and commercializes therapeutics in dermatology. Comparable as a dermatology-focused player working on skin-applied pharmaceutical products, though Dermavant is more developed and focused on delivering therapeutics rather than blocking absorption.

Emerging players

  • Aclaris Therapeutics: Aclaris Therapeutics is a clinical-stage biopharmaceutical company focused on dermatological and immunological conditions. Comparable as a small-cap dermatology biotech with a similar development-stage profile to CoLabs.

Market position

Strengths3 records

Weaknesses4 records

Competitive moat1 record

Key risks6 records

Key highlights3 records

Customer concentration

CoLabs social profiles

Digital presence

CoLabs financial estimates

Financial estimate

Revenue estimate

Valuation estimate

CoLabs leadership team

Management profile

Number of profiles

Profiles2 records

CoLabs funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

CoLabs M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about CoLabs

What does CoLabs do?

CoLabs develops consumer-facing biotechnology products intended to reduce the unwanted absorption of drugs into the skin. The company plans to distribute these topical barrier products directly to end consumers via its own e-commerce website (colabsintl.com). No specific named SKUs, pricing, or technical specifications are publicly disclosed, and the storefront remains in a "Launching Soon" pre-launch state.

Is CoLabs a public or private company?

CoLabs is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was CoLabs founded?

CoLabs was founded in 2008. It employs 1 to 10 people.

Where is CoLabs based?

CoLabs is headquartered in Huntington Beach, United States, in the North America region.

Who are CoLabs's main competitors?

Direct peers on record are Noven Pharmaceuticals, Crescita Therapeutics, AdhexPharma and Tapemark. Dermavant Sciences is listed as a broad incumbent. Aclaris Therapeutics is listed as an emerging player.

Does CoLabs have an API?

No public API is recorded for CoLabs.

What industry is CoLabs in?

CoLabs's product category is Topical Drug Delivery / Consumer Biotechnology. Its primary akta.pro industry code is CRADAHAL, Functional Beverages (Vitamins, Probiotics, Nootropics, etc.).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
EntarabiCOLABS launches Riyadh workspace campus backed by leading regional investorsCOLABS launched a 4,000 sqm workspace campus in northern Riyadh, entering Saudi Arabia with over $8 million in funding from regional investors. The campus will host over 500 members and is part of its expansion across the Middle East, North Africa, and Pakistan.ZawyaCOLABS launches Riyadh workspace campus backed by leading regional investorsCOLABS launched a 4,000 sqm workspace campus in northern Riyadh, backed by regional investors including Shorooq and Waseel Partners. The company has raised over $8 million and aims to become the largest workspace provider for startups and scaleups in the Middle East, North Africa, and Pakistan.PR NewswireCOLABS launches Riyadh workspace campus backed by leading regional investorsCOLABS, a Saudi community-led workspace platform, launched a 4,000 sqm campus in northern Riyadh, its entry into Saudi Arabia. The company has raised over $8 million from regional investors including Shorooq and Waseel Partners. It aims to become the largest workspace provider for startups and scaleups in the Middle East, North Africa, and Pakistan.SecSEC FORM DCoLabs Int'l, Corp. filed a Form D with the Securities and Exchange Commission to report an exempt offering of securities under Rule 504(b)(1). The company has sold $315,000 of its $600,000 total offering target to four investors as of May 2023.GlobeNewswireCoLabs Announces Regulation A+ Stock Offering in its Reimagined Skincare Delivery Technology QuantaSphere® and Growing BusinessCoLabs launched a Regulation A+ equity crowdfunding campaign after SEC qualification, seeking $19.5 million at $6.50 per share. The funds will support marketing, R&D, and expansion. The company's QuantaSphere technology is used in its KLĒNSKIN sunscreen and other products.